Copyright (c) 2009 Yahoo! Inc. All rights reserved.http://finance.yahoo.com/q/h?s=rgenLatest Financial News for Repligen Corporationen-usTue, 15 Dec 2009 14:00:00 Etc/GMThttp://us.news2.yimg.com/us.yimg.com/p/fi/pr/40197.gifhttp://finance.yahoo.com14417http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091215/ne25813.html?.v=1Repligen Corporation today announced that the Company has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich's ataxia from the Muscular Dystrophy Association .  This grant will support the completion of preclinical GLP toxicology testing and GMP manufacture of a drug candidate for human clinical trials.  Support from the MDA not only provides important funding for Repligen's research but it also provides access to a global network of scientists, physicians and patients.  This is the second research grant that Repligen has received from the MDA to support its Friedreich's ataxia program.yahoo_finance/95174769Tue, 15 Dec 2009 14:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/external/pssa/rss/SIG=12o194lua/*http%3A//seekingalpha.com/article/177997-biotech-s-latest-failed-trials-missed-targets?source=yahooyahoo_finance/2001761516Mon, 14 Dec 2009 09:22:35 Etc/GMThttp://us.rd.yahoo.com/finance/external/wsj/rss/SIG=12i07n6ts/*http%3A//online.wsj.com/article/SB10001424052748704240504574586043772389718.html?ru=yahoo&mod=yahoo_hsyahoo_finance/1610026613Wed, 9 Dec 2009 18:09:17 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/ap/091209/us_repligen_mover.html?.v=1Repligen Corp. said Wednesday its pancreas imaging agent RG1068 did not meet its main goal in a late-stage clinical study.yahoo_finance/3166692757Wed, 9 Dec 2009 15:37:49 Etc/GMThttp://us.rd.yahoo.com/finance/external/reuters/rss/SIG=118cks9u6/*http%3A//www.reuters.com/legacyArticle?duid=mtfh11808_2009-12-09_12-08-05_bng189747_newsml&rpc=44&type=marketsNewsyahoo_finance/260499388Wed, 9 Dec 2009 12:08:05 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091209/ne23276.html?.v=1Repligen Corporation reported today top-line results from a Phase 3 clinical trial to evaluate the safety and efficacy of RG1068, synthetic human secretin, to improve magnetic resonance imaging of the pancreas in patients with a history of pancreatitis.yahoo_finance/3234361153Wed, 9 Dec 2009 11:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091208/ne22834.html?.v=1Repligen Corporation announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Wednesday, December 9th, 2009 at 8:30 a.m.yahoo_finance/2126880727Tue, 8 Dec 2009 21:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/q/is?s=rgenyahoo_finance/2448045568Wed, 11 Nov 2009 14:05:11 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/a/r/r/rgen.htmlyahoo_finance/1073102003Sun, 8 Nov 2009 14:19:54 Etc/GMThttp://us.rd.yahoo.com/finance/external/trsa/rss/SIG=138qq1ejv/*http%3A//seekingalpha.com/article/171527-repligen-corp-f2q09-qtr-end-09-30-09-earnings-call-transcript?source=yahooyahoo_finance/2757172253Thu, 5 Nov 2009 17:46:07 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/cc/2/108912.htmlyahoo_finance/3085690798Thu, 5 Nov 2009 15:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091105/rgen8-k.htmlyahoo_finance/2174250522Thu, 5 Nov 2009 12:24:01 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/research/earncal/20091105.html?t=rgenyahoo_finance/2953924724Thu, 5 Nov 2009 12:07:32 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091105/ne05145.html?.v=1Repligen Corporation today reported results for the second quarter of fiscal year 2010, ended September 30, 2009.yahoo_finance/601084931Thu, 5 Nov 2009 12:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091103/ne04043.html?.v=1Repligen Corporation announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at the Merriman Curhan Ford 6th Annual Investor Summit on Tuesday, November 10th, 2009 at 1:40 p.m.yahoo_finance/497534905Tue, 3 Nov 2009 13:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091029/ne00561.html?.v=1Repligen Corporation announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, November 5th, 2009 at 10:00 a.m.yahoo_finance/3604212973Thu, 29 Oct 2009 12:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/cc/3/108573.htmlyahoo_finance/4054441270Fri, 23 Oct 2009 12:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091022/ne97271.html?.v=1Repligen Corporation announced today that it has entered into an exclusive license agreement with Families of Spinal Muscular Atrophy for intellectual property covering compounds which may have utility in treating Spinal Muscular Atrophy .yahoo_finance/1277328498Thu, 22 Oct 2009 20:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091019/ne94630.html?.v=1Repligen Corporation reported today that it has completed patient treatment in its Phase 3 clinical trial of RG1068, synthetic human secretin, in magnetic resonance imaging of the pancreas.yahoo_finance/3360454252Mon, 19 Oct 2009 17:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/090925/ne82016.html?.v=1Repligen Corporation reported today publication of research that identifies histone deacetylase 3 as an important enzyme target for therapeutic intervention in Friedreich's ataxia.yahoo_finance/151611866Fri, 25 Sep 2009 16:15:00 Etc/GMT